Terms: = Ovarian cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Prognosis
363 results:
1. A novel defined programmed cell death related gene signature for predicting the prognosis of serous ovarian cancer.
Zhan F; Guo Y; He L
J Ovarian Res; 2024 Apr; 17(1):92. PubMed ID: 38685095
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive analysis of the interaction of antigen presentation during anti-tumour immunity and establishment of AIDPS systems in ovarian cancer.
Sun W; Xu P; Gao K; Lian W; Sun X
J Cell Mol Med; 2024 Apr; 28(8):e18309. PubMed ID: 38613345
[TBL] [Abstract] [Full Text] [Related]
3. Pre-operative plasma VEGF-C levels portend recurrence in epithelial ovarian cancer patients and is a bankable prognostic marker even in the initial assessment of a patient.
Bhaskari J; Bhagat R; Shilpa V; Premalata CS; Krishnamoorthy L
J Ovarian Res; 2024 Apr; 17(1):77. PubMed ID: 38594780
[TBL] [Abstract] [Full Text] [Related]
4. Development and validation of an ultrasound-based deep learning radiomics nomogram for predicting the malignant risk of ovarian tumours.
Du Y; Xiao Y; Guo W; Yao J; Lan T; Li S; Wen H; Zhu W; He G; Zheng H; Chen H
Biomed Eng Online; 2024 Apr; 23(1):41. PubMed ID: 38594729
[TBL] [Abstract] [Full Text] [Related]
5. Histone modification-linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter.
Xiong J; Liang H; Sun X; Gao K
J Cell Mol Med; 2024 Apr; 28(8):e18260. PubMed ID: 38520216
[TBL] [Abstract] [Full Text] [Related]
6. Identification of prognostic factors and construction of nomogram to predict cancer-specific survival for patients with ovarian granulosa cell tumors.
Zhang Y; Zhang Z; Ding X; Zhang K; Dai Y; Cheng W; Luo C
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2046. PubMed ID: 38507268
[TBL] [Abstract] [Full Text] [Related]
7. 5 signature genes revealed by single-cell profiling identified unique immune subtypes affecting the prognosis of ovarian cancer.
Xiang SY; Li QK; Yang Z; Yi Q
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2051-2062. PubMed ID: 38497886
[TBL] [Abstract] [Full Text] [Related]
8. Unraveling the molecular mechanisms of lymph node metastasis in ovarian cancer: focus on MEOX1.
Li J; Sun Y; Zhi X; Sun Y; Abudousalamu Z; Lin Q; Li B; Yao L; Chen M
J Ovarian Res; 2024 Mar; 17(1):61. PubMed ID: 38486335
[TBL] [Abstract] [Full Text] [Related]
9. Development and clinical validation of a seven-gene signature based on tumor stem cell-related genes to predict ovarian cancer prognosis.
Wang G; Liu X; You Y; Chen S; Chang X; Yang Q
J Ovarian Res; 2024 Mar; 17(1):58. PubMed ID: 38481252
[TBL] [Abstract] [Full Text] [Related]
10. Survival time prediction in patients with high-grade serous ovarian cancer based on
He D; Zhang X; Chang Z; Liu Z; Li B
BMC Cancer; 2024 Mar; 24(1):337. PubMed ID: 38475819
[TBL] [Abstract] [Full Text] [Related]
11. setDB1 promotes progression through upregulation of SF3B4 expression and regulates the immunity in ovarian cancer.
Yang H; Sui L; Cai C; Chu H; Diao Y
J Ovarian Res; 2024 Feb; 17(1):34. PubMed ID: 38317200
[TBL] [Abstract] [Full Text] [Related]
12. PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/β-catenin signalling pathway.
Wu J; Wu Y; Chen S; Guo Q; Shao Y; Liu C; Lin K; Wang S; Zhu J; Chen X; Ju X; Xia L; Wu X
Oncogene; 2024 Mar; 43(12):866-883. PubMed ID: 38297082
[TBL] [Abstract] [Full Text] [Related]
13. Construction and validation of molecular subtype and signature of immune cell-related telomeric genes and prediction of prognosis and immunotherapy efficacy in ovarian cancer patients.
Ling L; Li B; Wu H; Zhang K; Li S; Ke B; Zhu Z; Liu T; Liu P; Zhang B
J Gene Med; 2024 Jan; 26(1):e3606. PubMed ID: 38282157
[TBL] [Abstract] [Full Text] [Related]
14. An immune-related exosome signature predicts the prognosis and immunotherapy response in ovarian cancer.
Zhu K; Ma J; Tian Y; Liu Q; Zhang J
BMC Womens Health; 2024 Jan; 24(1):49. PubMed ID: 38238671
[TBL] [Abstract] [Full Text] [Related]
15. Anoikis related genes may be novel markers associated with prognosis for ovarian cancer.
Yang C; Zhu L; Lin Q
Sci Rep; 2024 Jan; 14(1):1564. PubMed ID: 38238592
[TBL] [Abstract] [Full Text] [Related]
16. Identification and validation of anoikis-related lncRNAs for prognostic significance and immune microenvironment characterization in ovarian cancer.
Cao L; Zhang S; Peng H; Lin Y; Xi Z; Lin W; Guo J; Wu G; Yu F; Zhang H; Ye H
Aging (Albany NY); 2024 Jan; 16(2):1463-1483. PubMed ID: 38226979
[TBL] [Abstract] [Full Text] [Related]
17. Construction of monocyte-related prognosis model based on comprehensive analysis of bulk RNA-seq and single-cell RNA-seq in high-grade serous ovarian cancer.
Xu Y; Tan S; Huang W; Wang YX
Medicine (Baltimore); 2023 Dec; 102(50):e36548. PubMed ID: 38115318
[TBL] [Abstract] [Full Text] [Related]
18. Insulin-like growth factor 2 mRNA-binding protein 2 is a therapeutic target in ovarian cancer.
Yuan J; Li X; Wang F; Liu H; Guan W; Xu G
Exp Biol Med (Maywood); 2023 Dec; 248(23):2198-2209. PubMed ID: 38084732
[TBL] [Abstract] [Full Text] [Related]
19. Identification of a cancer associated fibroblasts-related index to predict prognosis and immune landscape in ovarian cancer.
Ye Y; Zhang S; Jiang Y; Huang Y; Wang G; Zhang M; Gui Z; Wu Y; Bian G; Li P; Zhang M
Sci Rep; 2023 Dec; 13(1):21565. PubMed ID: 38057405
[TBL] [Abstract] [Full Text] [Related]
20. Cuproptosis-related lncRNAs ovarian cancer: Multi-omics analysis of molecular mechanisms and potential therapeutic targets.
Wang Y; Liang Q; Xu L; Xiong J; Gao K; Xu P; Huang W
Environ Toxicol; 2024 Mar; 39(3):1650-1665. PubMed ID: 38019212
[TBL] [Abstract] [Full Text] [Related]
[Next]
